SEATTLE, Sept. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced that it had completed the previously announced sale of 23,121,394 shares of its common stock at a per share price of $1.73 per share in a registered offering. CTI has also granted the purchasing investors a 90-day option to purchase an additional 5,780,352 shares at the same price per share.
Rodman & Renshaw, LLC acted as the lead placement agent and sole book runner on this transaction. Punk, Ziegel and Company acted as the co-placement agent.
A shelf registration statement relating to the common stock issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
Cell Therapeutics, Inc.
CONTACT: Leah Grant, +1-206-272-4345, or Susan Callahan, +1-206-272-4472,both of Cell Therapeutics, Inc., fax, +1-206-272-4434, ormedia@ctiseattle.com, or invest@ctiseattle.com
Web site: http://www.cticseattle.com/
